1Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin Mechanism of action and an tineoplastic activity. Semin Oncol, 1998,25(2):4～ 12.
2Louvet C, Andre T, Tigaud JM, et al. Phase Ⅱ study of oxaliplatin fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol,2002,20(23) :4543 ～ 4548.
1De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
2Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
3Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
4De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
5De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
5Schucher LM,Luginbuhl WE,Meropol N J.The current status oft oxicity protectants in cancer therapy.SeminOncol,1992,19(6):742-751.
6CCapizzi RL.The preclinieal basis for broad-apectum selective cytoprotection of normal tissue from cytotoxic therapies by amifostine.Se2 minOncol,1999,26(2):3-21.
8Aizawa S, Nakano M, Lwase O, et al. Bonem arrow strow from re- fractory anemia of myelodysp lastic syndrome is defective in its ability to support normal CD34 -positive cell proliferation and differentiation in vitro[ J]. Leuk Res, 1999,23:239 - 246.
9Coutinho LH, Geary CG, Chang J, et al. Functional studies of bo- nem arrow haemopoietic and stromal cells in the myelodysp lasia syndrome(MDS) [ J]. BrJ Haematol, 1990,75 : 16 - 25.
